<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anesthetic considerations after heart transplantation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anesthetic considerations after heart transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anesthetic considerations after heart transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Antonio Hernandez Conte, MD, MBA, FASA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lorraine N Lubin, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan B Mark, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lena S Sun, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1959447404"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In the United States, the number of heart transplants has increased during the past several years, with more than 3000 performed in 2018 [<a href="#rid1">1,2</a>]. While the majority are performed in adult recipients, approximately 600 to 700 occur in patients &lt;18 years old. Due to the high rate of survival and increased life expectancy, adult and pediatric patients with heart transplants are likely to present for an elective or emergency noncardiac surgical procedure post-transplantation.</p><p>Heart transplant recipients present unique anesthetic challenges that include altered autonomic physiology and response to medications due to denervation of the donor heart, side effects of chronically administered immunosuppressive medications, and medical comorbidities. This topic will discuss anesthetic and perioperative management for heart transplant recipients who subsequently undergo a noncardiac surgical procedure. A separate topic addresses anesthetic management for heart transplantation surgery. (See  <a class="medical medical_review" href="/z/d/html/114430.html" rel="external">"Anesthesia for heart transplantation"</a>.)</p><p class="headingAnchor" id="H1193570678"><span class="h1">PREANESTHETIC ASSESSMENT</span></p><p class="headingAnchor" id="H3521258532"><span class="h2">General concerns for heart transplant recipients</span><span class="headingEndMark"> — </span>In adult patients, the one-year survival rate after heart transplantation is about 90 percent and the five-year rate is about 70 percent; however, only about 20 percent survive ≥20 years [<a href="#rid3">3</a>]. In pediatric patients, the one-year survival rate is approximately 80 to 90 percent and the five-year survival rate is 70 to 80 percent [<a href="#rid4">4</a>]. Some pediatric transplant recipients are in their 20s after heart transplantation and are in relatively good health. Such patients may eventually need a noncardiac surgical procedure. Several small studies have reported that 15 to 47 percent of heart transplant recipients subsequently undergo one or more noncardiac surgical procedures [<a href="#rid5">5-7</a>]. One retrospective study that included 207 post-transplantation patients noted that 35 percent subsequently underwent noncardiac surgery, and that urological procedures were the most commonly performed cases [<a href="#rid8">8</a>].</p><p>Both adult and pediatric cardiac transplant patients have complex medical considerations that require detailed assessment before planned noncardiac surgery. As noted below, specific concerns typically differ for patients in the early post-transplant period (first 6 to 12 months) compared with the later period (after 12 months). Preoperative assessment is accomplished in conjunction with the patient's heart transplant management team. Consultation is particularly important if a surgical procedure is necessary in the first 6 to 12 months after transplantation.</p><p class="headingAnchor" id="H1092737219"><span class="h2">Early post-transplantation period (6 to 12 months)</span><span class="headingEndMark"> — </span>During the first 6 to 12 months after transplantation, elective surgical procedures are deferred. During this period, patients have a greater risk of complications including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute rejection</strong> – Acute graft dysfunction secondary to rejection and ischemic injury often manifests as right ventricular dysfunction. During the preoperative assessment, tests of graft function are reviewed, including electrocardiograms, echocardiograms, angiograms, surveillance biomarkers such as B-type natriuretic peptide, endomyocardial biopsy results, and/or gene expression profiling. (See  <a class="medical medical_review" href="/z/d/html/3526.html" rel="external">"Heart transplantation in adults: Graft dysfunction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppression-related complications</strong> – Immunosuppressive medications are generally targeted at a higher therapeutic level during the first three to six months after cardiac transplantation, typically necessitating adrenal suppression prophylaxis (see <a class="local">'Adrenal suppression prophylaxis'</a> below). Notably, immunosuppression-related complications such as renal dysfunction from calcineurin inhibitors, steroid-induced diabetes, steroid-induced myopathy, leukopenia, and infection are more likely during this early post-transplantation period. Ideally, the patient should be on a stable immunosuppressive regimen prior to scheduling elective surgery. (See  <a class="medical medical_review" href="/z/d/html/3530.html" rel="external">"Heart transplantation in adults: Induction and maintenance of immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Immunosuppressive therapy increases infection risk. When feasible, surgery is deferred until any active infection has been treated. (See  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exacerbation of comorbidities</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Renal dysfunction</strong> – Preoperative renal insufficiency is often present as chronic renal hypoperfusion is common due to pre-transplantation heart failure. Other risk factors include post-transplantation nephrotoxic immunosuppressive regimes and repeated exposure to contrast media during cardiac catheterization procedures. The baseline creatinine level and glomerular filtration rate are noted, as well as urinalysis and spot urine albumin/creatinine ratio.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver dysfunction</strong> – Congestive hepatopathy is often present due to pre-transplantation heart failure, with variable improvement post-transplantation due to improved cardiac output. In particular, liver disease after a previous Fontan procedure followed by heart transplantation may be severe with congestive hepatopathy and fibrosis or cirrhosis (see  <a class="medical medical_review" href="/z/d/html/95232.html" rel="external">"Management of complications in patients with Fontan circulation", section on 'Liver disease'</a>). Also, patients with arrhythmias may be taking hepatotoxic medications such as <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>. The standard model for end-stage liver disease (MELD) scores are useful in determining severity of liver disease prior to noncardiac surgery in adult patients. (See  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)"</a>.)</p><p></p><p class="bulletIndent2">Liver function studies are reviewed during the preoperative assessment. These include the prothrombin time and international normalized ratio to assess potential liver-related coagulopathy, as well as bilirubin, aspartate aminotransferase, and alanine transaminase.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other common acute or chronic comorbidities</strong>. (See  <a class="medical medical_review" href="/z/d/html/3523.html" rel="external">"Heart transplantation in adults: Prognosis", section on 'Medical conditions after cardiac transplantation that may affect outcome'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Steroid-induced diabetes mellitus.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hypertension requiring treatment with antihypertensive therapy (typically angiotensin-converting enzyme inhibitors or angiotensin receptor blockers).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pulmonary diseases (eg, restrictive lung disease, reactive airway disease, recurrent pneumonias). A history of prolonged ventilatory support suggests underlying pulmonary dysfunction and risk for postoperative respiratory failure. The chest radiograph and any pulmonary function testing results are reviewed during the preanesthetic assessment.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Congenital anomalies in patients who have congenital heart disease (CHD). Examples include airway abnormalities, hypotonia, and pectus excavatum.</p><p></p><p class="headingAnchor" id="H1282229345"><span class="h2">Late post-transplantation period (&gt;12 months)</span><span class="headingEndMark"> — </span>After approximately one year post-transplantation, risk of acute rejection has diminished, and the immunosuppressive regimen has usually stabilized. Primary concerns during this period include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allograft vasculopathy</strong> – Allograft vasculopathy is a fibrous concentric intimal hyperplasia that extends for the length of the coronary arteries and is the predominant risk for graft dysfunction and chronic rejection in the late post-transplantation period. Right ventricular dysfunction, tricuspid regurgitation due to right ventricular dilation, and/or biventricular diastolic and systolic dysfunction may be noted on echocardiography. Patients with allograft vasculopathy are at risk for myocardial ischemia, intravascular volume overload, or arrhythmias during noncardiac procedures. As in the early post-transplantation period, cardiac studies are reviewed, including echocardiograms, angiograms, and the results of right heart catheterization and endomyocardial biopsy. (See  <a class="medical medical_review" href="/z/d/html/3522.html" rel="external">"Heart transplantation: Clinical manifestations, diagnosis, and prognosis of cardiac allograft vasculopathy"</a> and  <a class="medical medical_review" href="/z/d/html/3526.html" rel="external">"Heart transplantation in adults: Graft dysfunction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stability of the current immunosuppressive regimen</strong> – Typically, the immunosuppression regimen is stabilized in the first 6 months. Immunosuppression-related complications are less likely after the first 6 to 12 month period. (See  <a class="medical medical_review" href="/z/d/html/3530.html" rel="external">"Heart transplantation in adults: Induction and maintenance of immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of malignancy including post-transplant lymphoproliferative disease</strong> – Due to high-dose immunosuppression, malignancies are common in both children and adults after heart transplantation. Since these malignancies may involve the airway, careful examination for symptoms or signs of airway obstruction or potential difficulty with airway management is necessary. Details are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/275.html" rel="external">"Approach to the difficult airway in adults for emergency medicine and critical care", section on 'Identifying the anatomically difficult airway'</a> and  <a class="medical medical_review" href="/z/d/html/117124.html" rel="external">"Management of the difficult airway for pediatric anesthesia", section on 'Prediction of the pediatric difficult airway'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overall level of activity and exercise tolerance</strong> – These serve as indirect measures of cardiopulmonary function. In pediatric patients, normal growth and puberty progression is similar to age-matched non-transplant recipients in the absence of high-dose steroid therapy.</p><p></p><p class="headingAnchor" id="H4153689154"><span class="h1">ANESTHETIC MANAGEMENT AFTER PREVIOUS HEART TRANSPLANTATION</span></p><p class="headingAnchor" id="H3687384872"><span class="h2">Special considerations after heart transplantation</span><span class="headingEndMark"> — </span>There are several distinct changes in pharmacology and hemodynamic physiology after cardiac transplantation.</p><p class="headingAnchor" id="H3386043512"><span class="h3">Hemodynamic effects of denervation of the heart</span><span class="headingEndMark"> — </span>Cardiac autonomic denervation occurs due to explantation of the native heart during transplantation. This results in loss of autonomic nervous system innervation for both the parasympathetic and sympathetic responses. Visceral innervation is also lost. The following effects are evident:</p><p class="bulletIndent1"><span class="glyph">●</span>The graft heart usually has a higher resting heart rate (HR) at 90 to 130 beats per minute compared with a native heart due to lack of parasympathetic innervation, although HR may vary depending on the age of the graft.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Valsalva maneuvers and carotid massage are not effective.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Baroreceptor reflexes (eg, during tracheal intubation) are lost.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Starling effect is retained such that the denervated heart responds to increases in preload with an increase in stroke volume and cardiac output.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During episodes of myocardial ischemia, classic chest pain may not be experienced due to absent visceral innervation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The denervated heart is extremely dependent on adequate intravascular volume and preload. Although a compensatory reflex sympathetic tachycardic response cannot be mounted due to autonomic denervation, the Starling effect remains intact such that the heart will respond to increases in preload with increases in stroke volume and cardiac output. Administration of a direct-acting vasopressor agent is also effective to treat hypotension.</p><p></p><p class="headingAnchor" id="H1773354971"><span class="h3">Pharmacologic changes after denervation of the heart</span><span class="headingEndMark"> — </span>Responses to commonly used vasoactive agents and antiarrhythmic agents are affected by denervation of the transplanted heart:</p><p class="bulletIndent1"><span class="glyph">●</span>Indirectly-acting vasopressor agents that exert their effects via the autonomic nervous system (eg, <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a>) are ineffective, but direct-acting agents (eg, <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>) remain effective because the intrinsic alpha and beta receptors in the grafted heart are intact.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Responses to vasodilator agents (eg, <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a>, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>) and to anesthetic agents with vasodilatory effects (eg, <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>) may result in profound hypotension because the compensatory reflex tachycardic response is not present in a transplanted heart. To avoid or minimize hypotension, these agents are administered in small incremental doses or titrated very gradually</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticholinergic medications (eg, <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a>, <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a>) will not effectively treat bradycardia, but will retain their effects in noncardiac tissues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Direct-acting chronotropic agents (eg, <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">isoproterenol</a>) or techniques (eg, electrical pacing) are effective for treatment of bradyarrhythmias.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">Digoxin</a> (a commonly used antiarrhythmic and inotropic agent) will not have a rate-controlling effect, but will retain its inotropic effect.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">Adenosine</a>, which is a short-acting agent in a native heart, will have a significantly prolonged and profound bradycardic effect on a denervated heart.</p><p></p><p>Post-transplantation effects of commonly used anesthetic or adjuvant agents include:</p><p class="bulletIndent1"><span class="glyph">●</span>Neuromuscular blocking agents (NMBAs) such as <a class="drug drug_general" data-topicid="9738" href="/z/d/drug information/9738.html" rel="external">pancuronium</a> and <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> will not exert usual effects on HR, but will retain their extracardiac effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reversal agents for neuromuscular blockade that are acetylcholinesterase inhibitors such as <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">neostigmine</a> do not cause bradycardia. Nevertheless, rare cases of advanced heart block and asystole have been reported after neostigmine administration to heart transplant recipients [<a href="#rid9">9-13</a>], presumably due to some degree of parasympathetic reinnervation of the transplanted heart after a period of time [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">The newer reversal agent <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">sugammadex</a> acts via a different mechanism than acetylcholinesterase inhibitors and does not have cholinergic effects. However, it should also be used with caution in heart transplant recipients [<a href="#rid15">15</a>].</p><p></p><p class="headingAnchor" id="H1332033270"><span class="h3">Risk of myocardial ischemia</span><span class="headingEndMark"> — </span>Patients are at risk for myocardial ischemia due to transplant-related coronary artery disease (ie, cardiac allograft vasculopathy). Anesthetic management for patients with cardiac allograft vasculopathy is similar to that for other patients with ischemic heart disease. (See  <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">"Anesthesia for noncardiac surgery in patients with ischemic heart disease"</a>.)</p><p class="headingAnchor" id="H598607841"><span class="h3">Airway and ventilation considerations</span><span class="headingEndMark"> — </span>Oral rather than nasal endotracheal intubation is preferred to minimize infection risk in immunocompromised post-transplantation patients. However, a heightened bleeding risk may still exist, owing to gingival hyperplasia from <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, increased vascularity of mucosal surfaces due to collaterals in patients with CHD, and any chronically administered anticoagulant medications.</p><p>After intubation, hyperventilation is avoided because calcineurin inhibitors (ie, cyclosporin, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) administered as part of the immunosuppression regimen may decrease seizure thresholds.</p><p class="headingAnchor" id="H2777974254"><span class="h3">Adrenal suppression prophylaxis</span><span class="headingEndMark"> — </span>Almost all heart transplant recipients patients have a high likelihood of adrenal suppression due to chronic <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> administration. Supplemental glucocorticoids are given in accordance with the magnitude of the anticipated stress of the procedure  (<a class="graphic graphic_table graphicRef69479" href="/z/d/graphic/69479.html" rel="external">table 1</a>). Notably, the usual morning oral dose of glucocorticoid is always administered, regardless of whether additional glucocorticoid will be given just prior to the procedure. (See  <a class="medical medical_review" href="/z/d/html/146.html" rel="external">"The management of the surgical patient taking glucocorticoids", section on 'Perioperative glucocorticoids'</a>.)</p><p class="headingAnchor" id="H4161782780"><span class="h3">Surgical infection prophylaxis</span><span class="headingEndMark"> — </span>Antibiotic prophylaxis is administered according to institutional protocols. However, aminoglycosides and <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> are avoided due to the risk of renal injury when used with calcineurin inhibitors. (See  <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">"Antimicrobial prophylaxis for prevention of surgical site infection in adults"</a>.)</p><p class="headingAnchor" id="H2395932950"><span class="h2">Monitoring considerations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrocardiogram</strong> <strong>(ECG)</strong> – ECG abnormalities are common including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dual P waves due to the presence of native atrial cuff tissue and the transplanted atrium, which each generate electrical activity.</p><p class="bulletIndent2"><span class="glyph">•</span>Right bundle branch block due to frequent endomyocardial biopsies, which is present in up to 75 percent of transplant recipients.</p><p class="bulletIndent2"><span class="glyph">•</span>Atrial dysrhythmias due to the lack of vagal tone and increased endogenous catecholamine levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of invasive cardiovascular monitoring </strong>– Intraoperative invasive hemodynamic monitors (eg, intra-arterial blood pressure, central venous pressure, transesophageal echocardiography, or less frequently, a pulmonary artery catheter) are indicated if significant blood loss or large intravascular volume shifts are anticipated, particularly in post-transplant patients with evidence of cardiac dysfunction. Notably, frequent use of the right internal jugular vein for right heart catheterization and endomyocardial biopsy in post-transplantation patients may result in significant scarring and/or occlusion of this vessel. In general, the decision to use these additional monitors is guided by the same clinical considerations in cardiac transplant patients as would be used in other surgical patients.</p><p></p><p class="headingAnchor" id="H330722041"><span class="h2">Fluid and hemodynamic management</span><span class="headingEndMark"> — </span>It is critically important to avoid perioperative hypovolemia so that the transplanted heart has a mechanism to augment cardiac output in response to volume losses or vasodilation. Any loss of intravascular volume such as rapid blood loss or large fluid shifts must be immediately treated with volume administration to avoid decreased preload and significant hemodynamic instability. Some centers adjust anti-rejection medications when multiple units of blood products are transfused during the surgical procedure (eg, administration of pulse-dose <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> during the intraoperative and early postoperative periods) [<a href="#rid16">16</a>].</p><p>Severe hypotension can occur due to vasodilation after administration of certain intravenous or inhalation anesthetic agents or a neuraxial anesthetic technique. Administration of direct-acting vasopressors (eg, <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>, <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>, <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a>) is often necessary to treat hypotension. (See <a class="local">'Hemodynamic effects of denervation of the heart'</a> above.)</p><p class="headingAnchor" id="H2569061156"><span class="h2">Choice of anesthetic technique</span></p><p class="headingAnchor" id="H2906629345"><span class="h3">Monitored anesthesia care or peripheral nerve blocks</span><span class="headingEndMark"> — </span>Monitored anesthesia care with local anesthesia or a regional anesthetic technique, with or without light sedation, are acceptable anesthetic techniques when appropriate for selected planned noncardiac surgical procedures. An advantage of these techniques is absent or minimal hemodynamic consequences in heart transplant recipients.</p><p class="headingAnchor" id="H1602526837"><span class="h3">Neuraxial anesthesia</span><span class="headingEndMark"> — </span>Epidural or spinal neuraxial anesthetic techniques are also acceptable when appropriate for the planned surgical procedure. However, spinal or epidural blockade may cause severe hypotension in a post-transplant patient due to loss of sympathetic tone in the absence of normal compensatory reflexes that increase HR and preserve cardiac output (see <a class="local">'Hemodynamic effects of denervation of the heart'</a> above). Thus, a severe decrease in systemic vascular resistance may occur, with marked vasodilation, venous pooling, and decreased venous return to the heart. Pretreatment with infusion of crystalloid or colloid fluid (typically 500 to 1000 mL) at the time of placement of a neuraxial needle or catheter, in conjunction with administration of a direct-acting vasopressor such as <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>, may maintain preload and vascular tone to mitigate or avoid hypotension. (See  <a class="medical medical_review" href="/z/d/html/89517.html" rel="external">"Overview of neuraxial anesthesia", section on 'Cardiovascular'</a> and  <a class="medical medical_review" href="/z/d/html/4469.html" rel="external">"Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Hypotension'</a>.)</p><p class="headingAnchor" id="H958759649"><span class="h3">General anesthesia</span><span class="headingEndMark"> — </span>If general anesthesia is selected, the risk of hypotension during induction can be reduced by ensuring that intravascular volume status is adequate before anesthetic induction. Administration of a direct-acting vasopressor agent may also be necessary. (See <a class="local">'Hemodynamic effects of denervation of the heart'</a> above.)</p><p>Also, anesthetics are administered in incremental small bolus doses or are carefully titrated via inhalation or continuous intravenous infusion, particularly those agents with known vasodilatory properties. Examples include intravenous <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>, <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a>, or the potent volatile inhalation agents <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">sevoflurane</a> or <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">isoflurane</a>. (See <a class="local">'Hemodynamic effects of denervation of the heart'</a> above.)</p><p>For patients with hepatic or renal dysfunction, we select the NMBA <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">cisatracurium</a> because of its organ-independent metabolic profile via Hoffman elimination (see  <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Cisatracurium'</a>). General dosing considerations for anesthetic and adjuvant agents in patients with hepatic or renal dysfunction are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/91242.html" rel="external">"Anesthesia for the patient with liver disease", section on 'Effects of liver disease on anesthetic drug administration'</a> and  <a class="medical medical_review" href="/z/d/html/94254.html" rel="external">"Anesthesia for dialysis patients"</a> and  <a class="medical medical_review" href="/z/d/html/94254.html" rel="external">"Anesthesia for dialysis patients", section on 'General anesthesia'</a>.)</p><p class="headingAnchor" id="H334880003"><span class="h1">EARLY POSTOPERATIVE COMPLICATIONS</span><span class="headingEndMark"> — </span>Limited data are available regarding outcomes of post-cardiac transplantation patients undergoing noncardiac surgical procedures.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection </strong>– Patients are closely monitored for infection in the postoperative period. Bacterial infections such as sternal wound infections, pneumonia, and urinary tract infections are a significant risk even in patients who are not undergoing a surgical procedure, particularly in the early post-transplantation period (see <a class="local">'Early post-transplantation period (6 to 12 months)'</a> above). One retrospective study that included 116 noncardiac surgical procedures performed after previous heart transplantation noted that infection occurred in 7 percent of these procedures and was the most common postoperative complication [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exacerbation of renal or hepatic dysfunction </strong>- Patients are susceptible to exacerbation of chronic renal or hepatic insufficiency during and after additional surgical procedures performed after heart transplantation.</p><p></p><p class="headingAnchor" id="H1501778298"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special concerns after heart transplantation</strong> – Both adult and pediatric cardiac transplant patients have altered autonomic physiology and response to medications due to denervation of the donor heart, as well as side effects of chronically administered immunosuppressive medications, and complex medical comorbidities that require detailed assessment before planned noncardiac surgery. Preoperative assessment is accomplished in conjunction with the patient's heart transplant management team. (See <a class="local">'General concerns for heart transplant recipients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concerns in the first 6 to 12 months</strong> – During the first 6 to 12 months after transplantation, elective surgical procedures are deferred because patients have a greater risk of complications including (see <a class="local">'Early post-transplantation period (6 to 12 months)'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute graft dysfunction due to rejection </p><p class="bulletIndent2"><span class="glyph">•</span>Immunosuppression-related complications </p><p class="bulletIndent2"><span class="glyph">•</span>Infection</p><p class="bulletIndent2"><span class="glyph">•</span>Exacerbation of comorbidities</p><p class="bulletIndent3"><span class="glyph">-</span>Renal dysfunction</p><p class="bulletIndent3"><span class="glyph">-</span>Liver dysfunction</p><p class="bulletIndent3"><span class="glyph">-</span>Other common acute or chronic comorbidities (eg, steroid-induced diabetes mellitus, hypertension, pulmonary diseases, congenital anomalies)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concerns after 12 months</strong> – After approximately one year following heart transplantation, primary concerns differ and include (see <a class="local">'Late post-transplantation period (&gt;12 months)'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Allograft vasculopathy with myocardial ischemia</p><p class="bulletIndent2"><span class="glyph">•</span>Stability of the current immunosuppressive regimen</p><p class="bulletIndent2"><span class="glyph">•</span>Overall level of activity and exercise tolerance as indirect measures of cardiopulmonary function</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic alterations</strong> – Cardiac autonomic denervation occurs during transplantation, resulting in loss of autonomic nervous system innervation for both the parasympathetic and sympathetic responses, as well as loss of visceral innervation. Thus, only direct-acting vasoconstrictor agents (eg, <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>, <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a>) or chronotropic agents (eg, <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">isoproterenol</a>) are effective, while indirect-acting agents (eg, <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a>) and anticholinergic agents (eg, <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a>) are not effective. Also, hypotensive responses to vasodilator agents (eg, <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a>, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>) may result in profound hypotension. (See <a class="local">'Pharmacologic changes after denervation of the heart'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamic considerations</strong> – It is critically important to avoid perioperative hypovolemia so that the transplanted heart has a mechanism to augment cardiac output (CO) in response to volume losses or vasodilation. Losses of intravascular volume such as rapid blood loss or large fluid shifts are immediately treated with volume administration. Also, severe hypotension can occur due to vasodilation after administration of certain intravenous or inhalation anesthetic agents or a neuraxial anesthetic technique. Administration of direct-acting vasopressors (eg, <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>, <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>, <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a>) is often necessary to treat hypotension. (See <a class="local">'Hemodynamic effects of denervation of the heart'</a> above and <a class="local">'Fluid and hemodynamic management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring considerations</strong> – We<strong> </strong>typically use intraoperative invasive hemodynamic monitors (eg, intra-arterial blood pressure, central venous pressure, transesophageal echocardiography, or less frequently, a pulmonary artery catheter)<em> </em>if significant blood loss, large intravascular volume shifts are anticipated, particularly when cardiac dysfunction exists. (See <a class="local">'Monitoring considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of anesthetic technique</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitored anesthesia care with local or regional anesthesia</strong> – Monitored anesthesia care or regional anesthetic techniques such as peripheral nerve block(s) with or without light sedation are acceptable techniques when appropriate for selected planned noncardiac surgical procedures, having the advantage of absent or minimal hemodynamic consequences in heart transplant recipients. (See <a class="local">'Monitored anesthesia care or peripheral nerve blocks'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neuraxial anesthesia</strong> – Neuraxial (ie, spinal or epidural) anesthesia may result in severe hypotension from decreases in systemic vascular resistance, venous pooling, and decreased venous return to the heart due to sympathetic blockade in the absence of a compensatory tachycardic response and ability to preserve CO. (See <a class="local">'Neuraxial anesthesia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General anesthesia</strong> – If general anesthesia is selected, we reduce the risk of hypotension during induction by ensuring that intravascular volume status is adequate and administering a direct-acting vasopressor agent if necessary. Also, anesthetics are administered in incremental small bolus doses or are carefully titrated via inhalation or continuous intravenous infusion, particularly those agents with known vasodilatory properties. (See <a class="local">'General anesthesia'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">http://unos.org/data/ (Accessed on September 28, 2018).</li><li><a class="nounderline abstract_t">Colvin M, Smith JM, Hadley N, et al. OPTN/SRTR 2016 Annual Data Report: Heart. Am J Transplant 2018; 18 Suppl 1:291.</a></li><li><a class="nounderline abstract_t">Rossano JW, Dipchand AI, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant 2016; 35:1185.</a></li><li><a class="nounderline abstract_t">Dipchand AI. Current state of pediatric cardiac transplantation. Ann Cardiothorac Surg 2018; 7:31.</a></li><li><a class="nounderline abstract_t">Merhav H, Eisner S, Nakache R. Analysis of late operations in transplant patients. Transplant Proc 2004; 36:3083.</a></li><li><a class="nounderline abstract_t">Bhatia DS, Bowen JC, Money SR, et al. The incidence, morbidity, and mortality of surgical procedures after orthotopic heart transplantation. Ann Surg 1997; 225:686.</a></li><li><a class="nounderline abstract_t">Velanovich V, Ezzat W, Horn C, Bernabei A. Surgery in heart and lung transplant patients. Am J Surg 2004; 187:501.</a></li><li><a class="nounderline abstract_t">Marzoa R, Crespo-Leiro MG, Paniagua MJ, et al. Late noncardiac surgery in heart transplant patients. Transplant Proc 2007; 39:2382.</a></li><li><a class="nounderline abstract_t">Nkemngu NJ. Asystole following neuromuscular blockade reversal in cardiac transplant patients. Ann Card Anaesth 2017; 20:385.</a></li><li><a class="nounderline abstract_t">Backman SB, Stein RD, Ralley FE, Fox GS. Neostigmine-induced bradycardia following recent vs remote cardiac transplantation in the same patient. Can J Anaesth 1996; 43:394.</a></li><li><a class="nounderline abstract_t">Bjerke RJ, Mangione MP. Asystole after intravenous neostigmine in a heart transplant recipient. Can J Anaesth 2001; 48:305.</a></li><li><a class="nounderline abstract_t">Bertolizio G, Yuki K, Odegard K, et al. Cardiac arrest and neuromuscular blockade reversal agents in the transplanted heart. J Cardiothorac Vasc Anesth 2013; 27:1374.</a></li><li><a class="nounderline abstract_t">Beebe DS, Shumway SJ, Maddock R. Sinus arrest after intravenous neostigmine in two heart transplant recipients. Anesth Analg 1994; 78:779.</a></li><li><a class="nounderline abstract_t">Bernardi L, Valenti C, Wdowczyck-Szulc J, et al. Influence of type of surgery on the occurrence of parasympathetic reinnervation after cardiac transplantation. Circulation 1998; 97:1368.</a></li><li><a class="nounderline abstract_t">Yuki K, Scholl R. Should we Routinely Reverse Neuromuscular Blockade with Sugammadex in Patients with a History of Heart Transplantation? Transl Perioper Pain Med 2020; 7:185.</a></li><li><a class="nounderline abstract_t">Bachman SA, Chow VW, Kuwayama DP, Hickerson LC. Management of Hemorrhage and Heart Transplant in Non-Cardiac Surgery. J Cardiothorac Vasc Anesth 2020; 34:3078.</a></li></ol></div><div id="topicVersionRevision">Topic 122465 Version 5.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://unos.org/data/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : http://unos.org/data/ (Accessed on September 28, 2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29292604" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : OPTN/SRTR 2016 Annual Data Report: Heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27772670" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29492382" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Current state of pediatric cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15686700" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Analysis of late operations in transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9230809" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The incidence, morbidity, and mortality of surgical procedures after orthotopic heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15041499" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Surgery in heart and lung transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17889197" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Late noncardiac surgery in heart transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28701616" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Asystole following neuromuscular blockade reversal in cardiac transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8697556" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Neostigmine-induced bradycardia following recent vs remote cardiac transplantation in the same patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11305835" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Asystole after intravenous neostigmine in a heart transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23164506" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cardiac arrest and neuromuscular blockade reversal agents in the transplanted heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8135400" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Sinus arrest after intravenous neostigmine in two heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9577948" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Influence of type of surgery on the occurrence of parasympathetic reinnervation after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32039284" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Should we Routinely Reverse Neuromuscular Blockade with Sugammadex in Patients with a History of Heart Transplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32423735" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Management of Hemorrhage and Heart Transplant in Non-Cardiac Surgery.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
